{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T18:16:32Z","timestamp":1783188992989,"version":"3.54.6"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tisdale risk score has been validated for predicting drug-induced QTc prolongation (QTP) in cardiac care. This study aims to determine whether it can guide prescribing and monitoring of QTc-prolonging medications in primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective chart audit using Tisdale Risk Score was conducted. Data from 486 primary care patients from two Family Medicine Clinics, prescribed medications with known or possible risk of Torsades de Pointes (TdP) were reviewed. Eighty-five patients with pre- and post-pharmacotherapy ECGs comprised the cases. A control group of 184 patients not on QTc-prolonging medications was assessed. Patients were categorized as low, moderate, or high risk for QTP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Psychotropics were the most frequently prescribed QTc-prolonging medications. Baseline QTc did not differ significantly between cases (428\u2005ms) and controls (426\u2005ms). Among cases, most were stratified as low risk (69.4%), with fewer in moderate (25.9%) and high-risk (4.7%) categories. Comparatively, 99.5% of control patients were at low risk. QTc prolongation occurred in 5\/85 (5.9%) post-pharmacotherapy, with none in the high-risk category. Odds ratio for QTP in moderate-risk patients versus low-risk was 0.71 (95% CI: 0.07\u20136.98).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most primary care patients were at low risk for drug-induced QTc prolongation. QTP events were low with none in the high-risk category, which limited evaluation of association between risk categories and QTc prolongation. The study highlights commonly prescribed QTc-prolonging medications in family medicine and their variable QTc effects, emphasizing the need for an outpatient-tailored risk assessment tool.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/fampra\/cmag048","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:42:07Z","timestamp":1781782927000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessing the risk of drug-induced corrected QT interval prolongation in primary care"],"prefix":"10.1093","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-604X","authenticated-orcid":false,"given":"Divya","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Calgary , Calgary, Alberta , T2N4N1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal S","family":"Bhella","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Calgary , Calgary, Alberta , T2N4N1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trudy","family":"Huyghebaert","sequence":"additional","affiliation":[{"name":"School of Health and Wellness, Bow Valley College , Calgary, Alberta , T2G4V1","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"2026070413344432100_cmag048-B1","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026070413344432100_cmag048-B2","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug-induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"2026070413344432100_cmag048-B3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/europace\/eut214","article-title":"Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany","volume":"16","author":"Sarganas","year":"2014","journal-title":"Europace"},{"key":"2026070413344432100_cmag048-B4","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart rhythm society","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026070413344432100_cmag048-B5","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC)","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2026070413344432100_cmag048-B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026070413344432100_cmag048-B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can Pharm J (Ott)"},{"key":"2026070413344432100_cmag048-B8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","article-title":"Development of a risk score for QTc prolongation in the outpatient setting: the RISQ-PATH study","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"2026070413344432100_cmag048-B9","author":"Woosley"},{"key":"2026070413344432100_cmag048-B10","author":"Tees, Esk and Wear Valleys NHS Foundation Trust"},{"key":"2026070413344432100_cmag048-B11","doi-asserted-by":"publisher","first-page":"110138","DOI":"10.1016\/j.jpsychores.2020.110138","article-title":"QTc monitoring in adults with medical and psychiatric comorbidities: expert consensus from the association of medicine and psychiatry","volume":"135","author":"Xiong","year":"2020","journal-title":"J Psychosom Res"},{"key":"2026070413344432100_cmag048-B12","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"2026070413344432100_cmag048-B13","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/bjsm.2008.054734","article-title":"QTc: how long is too long?","volume":"43","author":"Johnson","year":"2009","journal-title":"Br J Sports Med"},{"key":"2026070413344432100_cmag048-B14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad Med J"}],"container-title":["Family Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/43\/4\/cmag048\/68697217\/cmag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/fampra\/article-pdf\/43\/4\/cmag048\/68697217\/cmag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:34:48Z","timestamp":1783186488000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/fampra\/article\/doi\/10.1093\/fampra\/cmag048\/8724927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6,11]]}},"URL":"https:\/\/doi.org\/10.1093\/fampra\/cmag048","relation":{},"ISSN":["0263-2136","1460-2229"],"issn-type":[{"value":"0263-2136","type":"print"},{"value":"1460-2229","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,11]]},"article-number":"cmag048"}}